May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Efficacy of Intravitreal Bevacizumab in Patients With Choroidal Neovascularization (CNV) in Angiod Streaks
Author Affiliations & Notes
  • C. Rosina
    University of Milan, Milano, Italy
    Ophthalmology/H. SACCO,
  • F. Viola
    University of Milan, Milano, Italy
    Ophthalmology/H. Maggiore,
  • P. Avanza
    University of Milan, Milano, Italy
    Ophthalmology,
  • G. Staurenghi
    University of Milan, Milano, Italy
    Ophthalmology/H. SACCO,
  • Footnotes
    Commercial Relationships C. Rosina, None; F. Viola, None; P. Avanza, None; G. Staurenghi, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 279. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Rosina, F. Viola, P. Avanza, G. Staurenghi; Efficacy of Intravitreal Bevacizumab in Patients With Choroidal Neovascularization (CNV) in Angiod Streaks. Invest. Ophthalmol. Vis. Sci. 2007;48(13):279.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy of intravitreal Bevacizumab in the treatment of CNV in patients with angioid streaks, unresponsives to photodynamic or laser therapy

Methods:: Retrospective chart review of 10 eyes treated with intravitreal (IVT) Bevacizumab (1.25mg) for CNV secondary to angioid streaks. The diagnosis of CNV was confirmed by fluorescein and indocyanine green angiography. Outcome measures included visual acuity (VA), retinal thickness with OCT, and degree of leakage on fluorescein and indocyanine green angiography.

Results:: At 1 month post injection in 5 of 10 (50%) eyes the fluorescein and indocyanine green angiography (FAG+ICGA) demonstrated decreased hyperfluorescence, the VA was stable and the OCT showed a decrease of retinal thickness, in 1 of 10 (10%) eyes decreased hyperfluorescence in angiogragraphy, decreased retinal thickness with OCT with decrease of VA, in 2 of 10 (20%) eyes VA, FAG+ICGA and OCT were stable with decreased metamorphopsia and in 2 of 10 (20%) eyes FAG+ICGA, OCT and VA were stable. At 3 months post injection VA, FAG+ICGA, OCT were stable in 10 of 10 (100%) eyes. At 6 months post injection we have the follow up of 7 eyes: in 5 of 7 (71,4%) eyes FAG+ ICGA, OCT and VA were stable, in 1(14,3%) eye FAG+ICGA demonstrated increased hyperfluorescence, OCT showed increased retinal thickness while the vision was stable, 1 (14,3%) patient presented metamorphopsia with FAG+ICGA, OCT and VA stable. After 6 months 2 of 7 (28,6%) eyes had a second IVT of bevacizumab. At 8 months post injection we have the follow up of 5 eyes: 2 of 5 (40%) eyes were stable, in 2 of 5 (40%) eyes the VA was stable but the FAG+ICGA demonstrated decreased hyperfluorescence and the OCT showed increased retinal thickness, in 1 of 5 (20%) eyes appeared metamorphopsia with vision, FAG+OCT and OCT stable. 3 eyes had a second injection of bevacizumab. At 1 year post injection we have the follow up of 1 eye: VA, angiography and OCT were stable.

Conclusions:: After 6 months in CNV angioid streaks Intravitreal Bevacizumab showed a good efficacy, in particular considering the effect of other previous treatments. Further clinical trials are needful to evaluate a longer follow-up.

Keywords: age-related macular degeneration • choroid: neovascularization • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×